Published in final edited form as:

ACS Catal. 2019 January 4; 9(1): 211–215. doi:10.1021/acscatal.8b04231.

Regioselective One-Pot Multienzyme (OPME) Chemoenzymatic Strategies for Systematic Synthesis of Sialyl Core 2 Glycans

Abhishek Santra, Yanhong Li, Tamashree Ghosh, Riyao Li, Hai Yu, and Xi Chen*

Department of Chemistry, University of California, One Shields Avenue, Davis, California 95616, United States

Abstract

O-GalNAc glycans or mucin-type glycans are common protein post-translational modifications in eukaryotes. Core 2 O-GalNAc glycans are branched structures that are broadly distributed in glycoproteins and mucins of all types of cells. To better understand their biological roles, it is important to obtain structurally defined Core 2 O-GalNAc glycans. We present here regioselective one-pot multienzyme (OPME) chemoenzymatic strategies to systematically access a diverse array of sialyl Core 2 glycans. Regioselectivity can be achieved by using OPME systems containing a glycosyltransferase with restricted acceptor specificity or by differentiating the branches using altered glycosylation sequences. This work provides a general regioselective strategy to access diverse Core 2 O-GalNAc glycans which can be extended for the synthesis of other complex branched glycans.

Graphical Abstract

Keywords

biocatalysis; enzymatic synthesis; glycosyltransferase; O-GalNAc glycan; sialyltransferase

O-GalNAc glycosylation at serine (Ser) or threonine (Thr) residues of proteins is a common protein post-translational modification (PTM) in eukaryotes. O-GalNAc glycans are also named as mucin-type O-glycans as they were initially found and are the most abundant in

*Corresponding Author: xiichen@ucdavis.edu.

ASSOCIATED CONTENT

Supporting Information.

This material is available free of charge via the Internet at <http://pubs.acs.org>.

Detailed synthetic procedures, nuclear magnetic resonance (NMR) spectroscopy and high-resolution mass spectrometry (HRMS) data, and NMR spectra of products (PDF)

mucins. All O-GalNAc glycans are extended from a monosaccharide *N*-acetylgalactosamine (GalNAc) that is α -linked to a serine or threonine residue (GalNAc α Ser/Thr) on glycoproteins. Most O-GalNAc glycans are derived from four major core structures namely Cores 1–4, including linear structures Gal β 1–3GalNAc α OR (Core 1) and GlcNAc β 1–3GalNAc α OR (Core 3) and branched structures Gal β 1–3(GlcNAc β 1–6)GalNAc α OR (Core 2) (**1** in Chart 1) and GlcNAc β 1–3(GlcNAc β 1–6)GalNAc α OR (Core 4).¹ The biosynthesis of these complex glycans is not template driven and the structures are more diverse and less predictable than their N-glycan counterparts in eukaryotes.²

Core 2 glycans are extended from Core 2 and are broadly distributed in glycoproteins and mucins of all types of cells.¹ Core 2 glycans have been found to be the major O-GalNAc glycans on glycoproteins of mouse zona pellucida (mZP) which are major oocyte surface glycoproteins and the targets of sperm binding for initiating fertilization.³ They have also been shown to influence the adhesion of Enteropathogenic *E. coli* (EPEC) and Enterohemorrhagic *E. coli* (EHEC) O157:H7 to human epithelial cell surface.⁴ Several common Core 2 glycans are shown in Chart 1. Among these, extended Core 2 tetrasaccharide Gal β 1–3(Gal β 1–4GlcNAc β 1–6)GalNAc α OR (**2**), disialyl Core 2 hexasaccharide Neu5Ac α 2–3Gal β 1–3(Neu5Ac α 2–3Gal β 1–4GlcNAc β 1–6)GalNAc α OR (**3**), monosialyl Core 2 pentasaccharides Gal β 1–3(Neu5Ac α 2–3Gal β 1–4GlcNAc β 1–6)GalNAc α OR (**4**) and Neu5Ac α 2–3Gal β 1–3(Gal β 1–4GlcNAc β 1–6)GalNAc α OR (**6**) and their fucosylated derivatives have been found in several breast cancer cell lines.⁵ Disialyl Core 2 hexasaccharide Neu5Ac α 2–3Gal β 1–3(Neu5Ac α 2–3Gal β 1–4GlcNAc β 1–6)GalNAc α OR (**3**) was also found as the major O-GalNAc glycan on glycocalicin released from human platelet membrane.^{6–7} While the major Core 2 glycan of human synovial lubricin and erythrocyte membrane glycoproteins of normal mice was found to be monosialyl Core 2 pentasaccharide Neu5Ac α 2–3Gal β 1–3(Gal β 1–4GlcNAc β 1–6)GalNAc α OR (**6**),^{8–9} monosialyl Core 2 tetrasaccharide Neu5Ac α 2–3Gal β 1–3(GlcNAc β 1–6)GalNAc α OR (**5**) was the major Core 2 glycan in β 1–4-galactosyltransferase I (GalT-I)-knock out mice.⁸ Disialyl Core 2 hexasaccharide with an α 2–6-linked sialic acid residue on the GlcNAc branch of the Core 2 structure and an α 2–3-linked sialic acid residue on the Gal branch Neu5Ac α 2–3Gal β 1–3(Neu5Ac α 2–6Gal β 1–4GlcNAc β 1–6)GalNAc α OR (**7**) was identified together with Core 2 glycans **2–4** and **6** in a glycan pool of advanced breast cancer serum MUC1.¹⁰

In order to elucidate their biological functions, it is necessary to obtain these structurally defined Core 2 O-GalNAc glycans in pure forms. Nevertheless, synthetic efforts in accessing these compounds have been limited. Chemical synthesis of sialylated Core 2 glycans¹¹ suffered from low overall yield because of the presence of one or more sialic acids which are challenging to introduce by chemical sialylation.^{12–14} Chemoenzymatic synthesis of various sialylated core 2 glycans was also reported using rat recombinant α 2–3-sialyltransferase and CMP-Neu5Ac.^{15–16} Recently, glycopeptides containing some of the Core 2 glycan structures were synthesized in small amounts for a competition enzyme-linked immunosorbent assay (ELISA)¹⁷ and mass spectrometry analysis.¹⁸ We report herein highly efficient regioselective one-pot multienzyme (OPME) chemoenzymatic strategies to

systematically access these important Core 2 glycans (**1–7**, Chart 1) using bacterial enzymes.

To facilitate product purification and reaction monitoring, a *p*-methoxyphenyl (PMP) group was installed at the reducing end of target Core 2 glycans. To allow regioselective enzymatic glycosylation of the Gal β 1–3- and GlcNAc β 1–6-branches of Core 2, PMP-tagged Core 2 trisaccharide Gal β 1–3(GlcNAc β 1–6)GalNAc α OR (**1**) was chemically synthesized from properly protected monosaccharide intermediates **8**,¹⁹ **9**,²⁰ and **10**²¹ by regio- and stereoselective glycosylation reactions. Briefly, iodonium ion-promoted stereoselective glycosylation of glycosyl acceptor **8** with thiotolyl glycoside derivative **9** using *N*-iodosuccinimide (NIS)-trimethylsilyl trifluoromethanesulfonate (TMSOTf) produced disaccharide derivative **11** in 84% yield (Scheme 1). It was converted to disaccharide diol derivative **12** in 92% yield using acetic acid-catalyzed selective deprotection of the benzylidene acetal group.²² Reactivity-based regio- and stereoselective glycosylation of glycosyl acceptor **12** with thiotolyl donor **10** in the presence of NIS-TMSOTf at –55 °C furnished trisaccharide derivative **13** in 78% yield. Compound **13** was subjected to a series of deprotection reactions including (a) transformation of *N*-phthaloyl group to acetamido group by the treatment with ethylene diamine followed by acetylation²³ using acetic anhydride and pyridine; (b) thioacetic acid-catalyzed one-pot conversion of azido to acetamido group;²⁴ and (c) saponification using sodium methoxide followed by purification using C18-column chromatography to afford the target Core 2 trisaccharide Gal β 1–3(GlcNAc β 1–6)GalNAc α OPMP (**1**) in three steps with an overall yield of 79%. The overall yield for synthesizing compound **1** from properly protected monosaccharide building blocks was 48% in six steps. This represents an improved synthetic route compared to the previous report of synthesizing a *p*-nitrophenyl glycoside of Core 2 trisaccharide (**1**) using a 4,6-di-*O*-benzoyl-2,3-*N,O*-oxazolidinone-protected donor with a step-by-step glycosylation process in an overall yields of 19%.²⁵ The current synthetic process is also more efficient than the reported chemoenzymatic synthesis of an octyl glycoside of Core 2 trisaccharide (**1**) in a 5 mg-scale which involved the chemical synthesis of Core 2 tetrasaccharide (**2**) using a [2+2] block glycosylation strategy with an overall 22% yield from properly protected monosaccharides followed by jack bean β -galactosidase-catalyzed reaction.²⁶

With the chemically synthesized Core 2 trisaccharide **1** in hand, neutral extended Core 2 tetrasaccharide Gal β 1–3(Gal β 1–4GlcNAc β 1–6)GalNAc α OPMP (**2**) containing both β 1–4- and β 1–3-linked galactoside branches was readily synthesized in 89% yield (Scheme 2) using an improved one-pot multienzyme (OPME) galactose (Gal)-activation and transfer system²⁷ containing *Streptococcus pneumoniae* TIGR4 galactokinase (SpGalK),²⁸ *Bifidobacterium longum* UDP-sugar pyrophosphorylase (BLUSP),²⁷ *Pasteurella multocida* pyrophosphatase (PmPpA),²⁹ and *Neisseria meningitidis* β 1–4-galactosyltransferase (NmLgtB)^{29–30} in Tris-HCl buffer (100 mM, pH 8.0) at 37 °C for 14 hours. SpGalK, BLUSP, and PmPpA allowed in situ formation of the donor substrate of NmLgtB, uridine 5'-diphosphate-galactose (UDP-Gal), from uridine 5'-triphosphate (UTP) and galactose-1-phosphate (Gal-1-P) formed from monosaccharide galactose (Gal) and adenosine 5'-triphosphate (ATP).

The purified extended Core 2 tetrasaccharide (**2**) was used as the acceptor substrate for sialylation using OPME α 2–3-sialylation system containing *Neisseria meningitidis* CMP-sialic acid synthetase (NmCSS)³¹ and an α 2–3-sialyltransferase. The most common sialic acid form, *N*-acetylneuraminic acid (Neu5Ac), was introduced. NmCSS was responsible for the formation of cytidine 5'-monophosphate *N*-acetylneuraminic acid (CMP-Neu5Ac), the donor substrate of sialyltransferases, from Neu5Ac and cytidine 5'-triphosphate (CTP). Two different α 2–3-sialyltransferases were used. The first one was *Pasteurella multocida* α 2–3-sialyltransferase 1 M144D (PmST1 M144D),³² a mutant engineered from wild-type multifunctional PmST1³³ to decrease its CMP-sialic acid (donor) hydrolysis activity (20-fold reduction) and α 2–3-sialidase activity (5588-fold decreased). Due to its high efficiency in sialylating both β 1–4- and β 1–3-linked galactosides in the extended Core 2 tetrasaccharide Gal β 1–3(Gal β 1–4GlcNAc β 1–6)GalNAc α OR (**2**), disialyl Core 2 hexasaccharide Neu5Ac α 2–3Gal β 1–3(Neu5Ac α 2–3Gal β 1–4GlcNAc β 1–6)GalNAc α OR (**3**) was readily produced in 73% yield (Scheme 2). The α 2–3-sialylation of both Gal residues in **3** was confirmed by comparing the chemical shifts of ¹³C nuclear magnetic resonance (NMR) data of compounds **2** and **3**. As shown in Table S1, signals for two newly added Neu5Ac residues were observed in compound **3**. In addition, the chemical shifts of C-3 (72.11 ppm and 72.00 ppm) of both β 1–4- and β 1–3-linked Gal residues in compound **2** were moved downfield to 75.11 ppm and 74.95 ppm, respectively, in compound **3**. These represented the most significant chemical shift changes and indicated the sites of sialylation.

The second sialyltransferase used was *Pasteurella multocida* α 2–3-sialyltransferase 3 (PmST3),³⁴ a monofunctional sialyltransferase that can use oligosaccharides, glycolipids, and glycopeptides³⁵ as acceptor substrates. Because of its preference in using β 1–4-linked galactosides but not β 1–3-linked galactosides as acceptor substrates,³⁴ OPME sialylation system containing PmST3 led to selective mono-sialylation of the β 1–4-linked galactoside branch of the tetrasaccharide **2** to form monosialylated Core 2 pentasaccharide Gal β 1–3(Neu5Ac α 2–3Gal β 1–4GlcNAc β 1–6)GalNAc α OR (**4**) in 83% yield (Scheme 3). The selective α 2–3-sialylation of compound **2** on the β 1–4-galactoside branch to form compound **4** was confirmed by comparing the ¹³C NMR data of compounds **2** and **4**. As shown in Table S1, the most significant changes on chemical shifts were the appearance of the signals for the newly added single Neu5Ac residue and downfield shift of the signal of the C-3 of β 1–4-linked Gal residue (72.11 ppm in **2** to 74.70 ppm in **4**).

The strategy for regioselective sialylation of the β 1–3-galactoside branch of the Core 2 was to use trisaccharide Gal β 1–3(GlcNAc β 1–6)GalNAc α OR (**1**) as the acceptor substrate in the OPME system containing NmCSS³¹ and PmST1 M144D³³ which can sialylate terminal galactose residue with either β 1–3- or β 1–4-linkage but not terminal *N*-acetylglucosamine (GlcNAc) residue. The Gal β 1- branch, not the GlcNAc β 1-branch, in Core 2 trisaccharide (**1**) was selectively sialylated to form monosialyl Core 2 tetrasaccharide Neu5Ac α 2–3Gal β 1–3(GlcNAc β 1–6)GalNAc α OR (**5**) in 94% yield (Scheme 3). Galactosylation of compound **5** using the same OPME β 1–4-galactosylation system described above for the synthesis of **2** from **1** led to the formation of monosialyl Core 2 pentasaccharide Neu5Ac α 2–3Gal β 1–3(Gal β 1–4GlcNAc β 1–6)GalNAc α OR (**6**) with the sialylation on the β 1–3-linked galactoside branch of the Core 2 glycan in 91% yield. Final sialylation using an OPME α 2–

6-sialylation system containing NmCSS and *Photobacterium species* α 2–6-sialyltransferase³⁶ A366G mutant (Psp2,6ST A366G)³⁶ with improved expression level and slightly increased activity successfully synthesized disialyl Core 2 hexasaccharide Neu5Ac α 2–3Gal β 1–3(Neu5Ac α 2–6Gal β 1–4GlcNAc β 1–6)GalNAc α OR (**7**) containing both α 2–3- and α 2–6-linked sialic acid residues at desired sites in 84% yield. The α 2–3-sialylation of β 1–3-linked galactoside branch in compound **6** was confirmed by comparing the ¹³C NMR data of compounds **2** and **6** (Table S1) by the presence of the signals of a single Neu5Ac residue in compound **6** and the downfield shift of the signal for the C-3 of β 1–3-linked Gal residue from 72.00 ppm in compound **2** to 75.16 ppm in compound **6**. Similarly, disialylation in compound **7** was obvious as the signals for two Neu5Ac residues were observed. The significant downfield shifts of C-3 of β 1–3-linked Gal (72.00 ppm in **2** and 75.15 ppm in **7**) and C-6 of β 1–4-linked Gal (60.51 ppm in **2** and 62.77 ppm in **7**) were clear by comparing the ¹³C NMR data of compounds **2** and **7**, which showed the sites of the sialylation.

In conclusion, regioselective one-pot multienzyme (OPME) chemoenzymatic strategies have been developed for systematic accessing a library of Core 2 O-GalNAc glycans. Regioselective sialylation was successfully achieved by using sialyltransferases with restricted acceptor specificity such as PmST3 and by differentiating the branches of chemically synthesized Core 2 trisaccharide **1** for sialylation using altered OPME glycosylation sequences. The two general regioselective strategies demonstrated here can be extended for the chemoenzymatic synthesis of other complex branched glycans.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENT

This work was supported by the United States National Institutes of Health (NIH) grants R01AI130684 and U01GM120419. Bruker Avance-800 NMR spectrometer was funded by NSF grant DBIO-722538.

REFERENCES

- (1). Brockhausen I; Stanley P O-GalNAc Glycans In Essentials of Glycobiology, 3rd Ed, Varki A; Cummings RD; Esko JD; Stanley P; Hart GW; Aebi M; Darvill AG; Kinoshita T; Packer NH; Prestegard JH; Schnaar RL; Seeberger PH Eds. Cold Spring Harbor (NY), 2015, pp 113–123.
- (2). Hanisch FGO-Glycosylation of The Mucin Type. Biol. Chem. 2001, 382, 143–149. [PubMed: 11308013]
- (3). Easton RL; Patankar MS; Lattanzio FA; Leaven TH; Morris HR; Clark GF; Dell A Structural Analysis of Murine Zona Pellucida Glycans. Evidence for The Expression of Core 2-Type O-Glycans and The Sda Antigen. J. Biol. Chem. 2000, 275, 7731–7742. [PubMed: 10713085]
- (4). Ye J; Song L; Liu Y; Pan Q; Zhong X; Li S; Shang Y; Tian Y; He Y; Chen L; Chen W; Peng Z; Wang R Core 2 Mucin-Type O-Glycan Is Related to EPEC and EHEC O157:H7 Adherence to Human Colon Carcinoma HT-29 Epithelial Cells. Dig. Dis. Sci. 2015, 60, 1977–1990. [PubMed: 25701318]
- (5). Muller S; Hanisch FG Recombinant MUC1 Probe Authentically Reflects Cell-Specific O-Glycosylation Profiles of Endogenous Breast Cancer Mucin. High Density and Prevalent Core 2-Based Glycosylation. J. Biol. Chem. 2002, 277, 26103–26112. [PubMed: 12000758]

- (6). Korrel SA; Clemetson KJ; Van Halbeek H; Kamerling JP; Sixma JJ; Vliegenthart JF Structural Studies on The O-Linked Carbohydrate Chains of Human Platelet Glycocalicin. *Eur. J. Biochem.* 1984, 140, 571–576. [PubMed: 6327299]
- (7). Tsuji T; Tsunehisa S; Watanabe Y; Yamamoto K; Tohyama H; Osawa T The Carbohydrate Moiety of Human Platelet Glycocalicin. *J. Biol. Chem.* 1983, 258, 6335–6339. [PubMed: 6406478]
- (8). Kotani N; Asano M; Iwakura Y; Takasaki S Impaired Galactosylation of Core 2 O-Glycans in Erythrocytes of β 1,4-Galactosyltransferase Knockout Mice. *Biochem. Biophys. Res. Commun.* 1999, 260, 94–98. [PubMed: 10381349]
- (9). Estrella RP; Whitelock JM; Packer NH; Karlsson NG The Glycosylation of Human Synovial Lubricin: Implications for Its Role in Inflammation. *Biochem. J.* 2010, 429, 359–367. [PubMed: 20443780]
- (10). Storr SJ; Royle L; Chapman CJ; Hamid UM; Robertson JF; Murray A; Dwek RA; Rudd PM The O-Linked Glycosylation of Secretory/shed MUC1 from An Advanced Breast Cancer Patient's Serum. *Glycobiology* 2008, 18, 456–462. [PubMed: 18332077]
- (11). Xia J; Alderfer JL; Srikrishnan T; Chandrasekaran EV; Matta KL A Convergent Synthesis of Core 2 Branched Sialylated and Sulfated Oligosaccharides. *Bioorg. Med. Chem.* 2002, 10, 3673–3684. [PubMed: 12213483]
- (12). Boons GJ; Demchenko AV Recent Advances in O-Sialylation. *Chem. Rev.* 2000, 100, 4539–4566. [PubMed: 11749357]
- (13). Halcomb RL; Chappell MD Recent Developments in Technology for Glycosylation with Sialic Acid. *J. Carbohydr. Chem.* 2002, 21, 723–768.
- (14). Chen X; Varki A Advances in the biology and chemistry of sialic acids. *ACS Chem Biol* 2010, 5, 163–176. [PubMed: 20020717]
- (15). Sengupta P; Misra AK; Suzuki M; Fukuda M; Hindsgaul O Chemoenzymatic Synthesis of Sialylated Oligosaccharides for Their Evaluation in A Polysialyltransferase Assay. *Tetrahedron Lett.* 2003, 44, 6037–6042.
- (16). Gutierrez Gallego R; Dudziak G; Kragl U; Wandrey C; Kamerling JP; Vliegenthart JFG Enzymatic Aynthesis of The Core-2 Sialyl Lewis X O-Glycan on The Tumor-Associated MUC1a' Peptide. *Biochimie* 2003, 85, 275–286. [PubMed: 12770766]
- (17). Ohyabu N; Hinou H; Matsushita T; Izumi R; Shimizu H; Kawamoto K; Numata Y; Togame H; Takemoto H; Kondo H; Nishimura S An Essential Epitope of Anti-MUC1 Monoclonal Antibody KL-6 Revealed by Focused Glycopeptide Library. *J. Am. Chem. Soc.* 2009, 131, 17102–17109. [PubMed: 19899793]
- (18). Pett C; Nasir W; Sihlbom C; Olsson BM; Caixeta V; Schorlemer M; Zahedi RP; Larson G; Nilsson J; Westerlind U Effective Assignment of α 2,3/ α 2,6-Sialic Acid Isomers by LC-MS/MS-Based Glycoproteomics. *Angew. Chem. Int. Ed. Engl.* 2018, 57, 9320–9324. [PubMed: 29742324]
- (19). Santra A; Ghosh T; Misra AK Expedient Synthesis of Two Structurally Close Tetrasaccharides Corresponding to The O-Antigens of Escherichia coli O127 and Salmonella enterica O13. *Tetrahedron: Asymm.* 2012, 23, 1385–1392.
- (20). Sethi KP; Kartha KPR Solvent-Free Bismuth Oxycarbonate-Mediated Mechanochemical Glycosylation: A Simple Greener Alternative to Access O-/S-Glycosides Efficiently. *Carbohydr. Res.* 2016, 434, 132–135. [PubMed: 27644088]
- (21). Lin Y-Y; Chan S-H; Juang Y-P; Hsiao H-M; Guh J-H; Liang P-H Design, Synthesis and Cytotoxic Activity of N-Modified Oleanolic Saponins Bearing A Glucosamine. *Eur. J. Med. Chem.* 2018, 143, 1942–1958. [PubMed: 29133061]
- (22). Chida N; Ohtsuka M; Nakazawa K; Ogawa S Total Synthesis of Antibiotic Hygromycin A. *J. Org. Chem.* 1991, 56, 2976–2983.
- (23). Santra A; Yu H; Tasnima N; Muthana MM; Li Y; Zeng J; Kenyon NJ; Louie AY; Chen X Systematic Chemoenzymatic Synthesis of O-Sulfated Sialyl Lewis x Antigens. *Chem. Sci.* 2016, 7, 2827–2831. [PubMed: 28138383]
- (24). Shangguan N; Katukojvala S; Greenberg R; Williams LJ The Reaction of Thio Acids with Azides: A New Mechanism and New Synthetic Applications. *J. Am. Chem. Soc.* 2003, 125, 7754–7755. [PubMed: 12822965]

- (25). Hollinger M; Abraha F; Oscarson S Synthesis of Mucin O-Glycan Core Structures as Their p-Nitro- and p-Aminophenyl Glycosides. *Carbohydr. Res.* 2011, 346, 1454–1466. [PubMed: 21514575]
- (26). Misra AK; Fukuda M; Hindsgaul O Efficient Synthesis of Lactosaminylated Core-2 O-Glycans. *Bioorg. Med. Chem. Lett.* 2001, 11, 2667–2669. [PubMed: 11591497]
- (27). Chen M; Chen LL; Zou Y; Xue M; Liang M; Jin L; Guan WY; Shen J; Wang W; Wang L; Liu J; Wang PG Wide Sugar Substrate Specificity of Galactokinase from *Streptococcus pneumoniae* TIGR4. *Carbohydr. Res.* 2011, 346, 2421–2425. [PubMed: 21903203]
- (28). Muthana MM; Qu J; Li Y; Zhang L; Yu H; Ding L; Malekan H; Chen X Efficient One-Pot Multienzyme Synthesis of UDP-Sugars Using A Promiscuous UDP-Sugar Pyrophosphorylase from *Bifidobacterium longum* (BLUSP). *Chem. Commun.* 2012, 48, 2728–2730.
- (29). Lau K; Thon V; Yu H; Ding L; Chen Y; Muthana MM; Wong D; Huang R; Chen X Highly Efficient Chemoenzymatic Synthesis of Beta1–4-Linked Galactosides with Promiscuous Bacterial Beta1–4-Galactosyltransferases. *Chem. Commun.* 2010, 46, 6066–6068.
- (30). Li Y; Xue M; Sheng X; Yu H; Zeng J; Thon V; Chen Y; Muthana MM; Wang PG; Chen X Donor Substrate Promiscuity of Bacterial beta1–3-N-Acetylglucosaminyltransferases and Acceptor Substrate Flexibility of beta1–4-Galactosyltransferases. *Bioorg. Med. Chem.* 2016, 24, 1696–1705. [PubMed: 26968649]
- (31). Yu H; Yu H; Karpel R; Chen X Chemoenzymatic Synthesis of CMP-Sialic Acid Derivatives by A One-Pot Two-Enzyme System: Comparison of Substrate Flexibility of Three Microbial CMP-Sialic Acid Synthetases. *Bioorg. Med. Chem.* 2004, 12, 6427–6435. [PubMed: 15556760]
- (32). Sugiarto G; Lau K; Qu J; Li Y; Lim S; Mu S; Ames JB; Fisher AJ; Chen X A Sialyltransferase Mutant with Decreased Donor Hydrolysis and Reduced Sialidase Activities for Directly Sialylating Lewis^x. *ACS Chem. Biol.* 2012, 7, 1232–1240. [PubMed: 22583967]
- (33). Yu H; Chokhawala H; Karpel R; Yu H; Wu B; Zhang J; Zhang Y; Jia Q; Chen X A Multifunctional *Pasteurella multocida* Sialyltransferase: A Powerful Tool for The Synthesis of Sialoside Libraries. *J. Am. Chem. Soc.* 2005, 127, 17618–17619. [PubMed: 16351087]
- (34). Thon V; Li Y; Yu H; Lau K; Chen X PmST3 from *Pasteurella multocida* Encoded by Pm1174 Gene Is A Monofunctional Alpha2–3-Sialyltransferase. *Appl. Microbiol. Biotechnol.* 2012, 94, 977–985. [PubMed: 22075637]
- (35). Malekan H; Fung G; Thon V; Khedri Z; Yu H; Qu J; Li Y; Ding L; Lam KS; Chen X One-Pot Multi-Enzyme (OPME) Chemoenzymatic Synthesis of Sialyl-Tn-MUC1 and Sialyl-T-MUC1 Glycopeptides Containing Natural or Non-natural Sialic Acid. *Bioorg. Med. Chem.* 2013, 21, 4778–4785. [PubMed: 23535562]
- (36). Ding L; Yu H; Lau K; Li Y; Muthana S; Wang J; Chen X Efficient Chemoenzymatic Synthesis of Sialyl Tn-Antigens and Derivatives. *Chem. Commun.* 2011, 47, 8691–8693.

Scheme 1.

Chemical synthesis of Core 2 trisaccharide (1). Reagents and conditions: (a) *N*-iodosuccinimide (NIS), TMSOTf, MS 4 Å, CH₂Cl₂, -25 °C, 1 h, 84%; (b) 80% acetic acid in water, 80 °C, 3 h, 92%; (c) *N*-iodosuccinimide (NIS), TMSOTf, MS 4 Å, CH₂Cl₂, -55 °C, 1 h, 78%; (d) (i) H₂N(CH₂)₂NH₂, *n*-BuOH, 90 °C, 8 h; (ii) pyridine, Ac₂O, r.t., 14 h; (e) pyridine, thioacetic acid, r.t., 18 h; (f) 0.1 M NaOMe, MeOH, r.t., 14 h; 79% in three steps.

Scheme 2.

Sequential one-pot multienzyme (OPME) synthesis of extended Core 2 tetrasaccharide (2) by OPME β1–4-galactosylation, disialyl Core 2 hexasaccharide (3) using PmST1 M144D in OPME sialylation reaction, and monosialyl Core 2 pentasaccharide (4) using PmST3 in OPME sialylation reaction.

Scheme 3.

Sequential one-pot multienzyme (OPME) synthesis of monosialyl Core 2 tetrasaccharide (5) using PmST1 M144D in OPME sialylation reaction, monosialyl Core 2 pentasaccharide (6) by OPME β 1–4-galactosylation, and disialyl Core 2 hexasaccharide (7) using Psp2,6ST A366G in OPME sialylation reaction.

Chart 1.

Structures of O-GalNAc Core 2 glycans (1–7) that are synthesized in the current study.